Peptides for male sexual dysfunction: a systematic review of emerging evidence.
Melanocortin receptor agonists like PT-141 show promise for improving erectile function in men, but more research is needed to confirm their effectiveness and safety.
Where it sits
this study against the rest of the pt-141 (bremelanotide) corpusSummary and findings
This systematic review evaluated the effects of peptide therapies on male sexual function, reproductive hormones, and semen parameters in adult men. A total of 372 male participants across twelve studies were included. The review found that melanocortin receptor agonists, including PT-141, showed consistent improvements in erectile function.
Abstract
<h4>Background</h4>Sexual dysfunction remains highly prevalent among men and significantly impacts quality of life. Peptides are short chains of amino acids designed to mimic endogenous signaling molecules and modulate a variety of physiological pathways.<h4>Aim</h4>To systematically review the available human evidence evaluating the effects of peptide and peptide-derived therapies on male sexual function, reproductive hormones, and semen parameters.<h4>Methods</h4>A systematic review was conducted according to PRISMA guidelines. PubMed, Scopus, and Web of Science were searched. Eligible studies included randomized controlled trials, crossover studies, prospective clinical studies, and experimental physiological studies evaluating peptide-based interventions in adult men.<h4>Outcomes</h4>Outcomes of interest included erectile function, sexual desire, orgasmic and ejaculatory outcomes, reproductive hormones, semen parameters, and adverse events.<h4>Results</h4>Twelve studies comprising 372 male participants met inclusion criteria. Investigated peptides included melanocortin receptor agonists (PT-141/bremelanotide and Melanotan II), kisspeptin analogues, and oxytocin. Melanocortin receptor agonists demonstrated the most consistent improvements in erectile function, producing significant increases in penile rigidity and erectile duration in healthy men and men with erectile dysfunction, including sildenafil non-responders. Kisspeptin increased gonadotropin secretion, enhanced sexual brain processing, and improved penile tumescence and measures of sexual desire in men with hypoactive sexual desire disorder. Oxytocin showed mixed effects, with potential benefits on orgasm intensity, sexual satisfaction, and partner interaction, but no consistent improvements in erectile function, ejaculation latency, or semen parameters.<h4>Clinical implications</h4>Peptide-based interventions may influence male sexual health through distinct peripheral, central, endocrine, and relational mechanisms, offering potential adjuncts or second-line alternatives for men who have failed or are intolerant of first-line pharmacotherapy.<h4>Strengths and limitations</h4>Strengths include the synthesis of human clinical evidence across multiple peptide classes and principal domains of male sexual function. Overall, studies were limited by small sample sizes, heterogeneous populations, short follow-up durations, and a lack of comparative studies.<h4>Conclusion</h4>Melanocortin receptor agonists currently have the strongest evidence for improving erectile outcomes, while kisspeptin represents a promising emerging therapy for sexual desire and reproductive endocrine modulation. However, the evidence base remains limited, and further studies are required before these therapies can be incorporated into routine clinical practice.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.